Compare Agilent Technologies Inc (A) vs Axogen Inc (AXGN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Axogen Inc — how do they compare? Agilent Technologies Inc trades at $128.2 (market cap $37.04B), while Axogen Inc trades at $43.01 (market cap $2.37B). The key difference: Agilent Technologies Inc is far larger — about 15.6× Axogen Inc's market cap, and Agilent Technologies Inc pays a 0.78% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| A | AXGN | |
|---|---|---|
Market Cap | $37.04B | $2.37B |
Sector | Health | Technology |
52-Week High | $157.20 | $46.19 |
52-Week Low | $110.24 | $11.28 |
Enterprise Value | $38.59B | $2.29B |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
AXGN trades at $45.97, up 0.17% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q1 2026 earnings of $0.07 per share, missing estimates, yet maintains a strong gross margin of 75.01%. Recent news highlights a bullish rebound and raised 2026 guidance, with 84% of analysts rating it a Buy. Support is at $44, with resistance at $47.
Outlook is cautiously optimistic due to strong analyst support and recent institutional interest, but risks include consecutive earnings misses and negative net income margins. The consensus price target of $47.60 suggests modest upside, though execution on guidance and reimbursement wins are critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →
